110020 — Jeonjin Bio Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩31bn
- KR₩31bn
- KR₩16bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1,462 | -3,418 | -2,108 | -3,154 | -6,440 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 30.5 | 1,640 | -629 | 157 | 5,282 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -293 | -972 | -14.3 | -2,105 | -979 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1,299 | -2,310 | -2,385 | -3,710 | -301 |
Capital Expenditures | -722 | -5,837 | -1,933 | -2,129 | -672 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -77.8 | 0.82 | 75 | -2,177 | 638 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -800 | -5,836 | -1,858 | -4,306 | -33.5 |
Financing Cash Flow Items | -172 | -196 | -30.9 | -726 | -689 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 924 | 12,909 | 10,629 | -5,928 | 694 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -1,170 | 4,760 | 6,383 | -13,971 | 358 |